Point72 Asset Management
APGE

Point72 Asset Management’s Apogee Therapeutics APGE Stock Holding History

Point72 Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.24M Buy
+54,559
New +$4.92M 0.01% 1506
2025
Q3 		– Sell
-1,230,377
Closed -$53.4M – 2295
2025
Q2 		$53.4M Buy
1,230,377
+837,889
+213% +$31.9M 0.1% 239
2025
Q1 		$14.7M Buy
392,488
+89,753
+30% +$3.47M 0.03% 544
2024
Q4 		$13.7M Sell
302,735
-404,533
-57% -$20.6M 0.03% 592
2024
Q3 		$41.5M Buy
707,268
+438,036
+163% +$21M 0.11% 226
2024
Q2 		$10.6M Sell
269,232
-217,968
-45% -$10.6M 0.03% 594
2024
Q1 		$32.4M Sell
487,200
-221,200
-31% -$9.66M 0.08% 307
2023
Q4 		$19.8M Buy
708,400
+335,292
+90% +$6.72M 0.05% 427
2023
Q3 		$7.95M Buy
+373,108
New +$8.22M 0.02% 727

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Point72 Asset Management's APGE Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 54,559 shares worth $7.24M. The stake represents 0.01% of the portfolio and ranks #1506 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in APGE as recently as Q2 2025.

Point72 Asset Management first reported a position in APGE in Q3 2023 and has held it in 9 quarters since. The position peaked at $53.4M in Q2 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Point72 Asset Management held 54,559 shares of Apogee Therapeutics worth $7.24M as of Q2 2026.
  • Apogee Therapeutics was a new Point72 Asset Management position in Q2 2026.
  • Apogee Therapeutics made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1506 holding.
  • Point72 Asset Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • Point72 Asset Management's Apogee Therapeutics position peaked at $53.4M in Q2 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.